|
Title
|
|
|
|
Interferon may be back on track to treat acute myeloid leukemia
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Our own experience and a thorough literature review suggest that interferon α (IFNα) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFNα for several months, which can be obtained by using pegylated IFNα. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Oncoimmunology
|
|
|
Publication
|
|
|
|
2013
|
|
|
ISSN
|
|
|
|
2162-4011
2162-402X
|
|
|
DOI
|
|
|
|
10.4161/ONCI.23619
|
|
|
Volume/pages
|
|
|
|
2
:4
(2013)
|
|
|
Article Reference
|
|
|
|
e23619
|
|
|
ISI
|
|
|
|
000322566200015
|
|
|
Medium
|
|
|
|
E-only publicatie
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|